ESR1 and cancer: In the adjuvant setting, the positive outcomes of the OlympiA trial in terms of progression-free survival but also overall survival [14] suggest that PARPi therapy is becoming a standard adjuvant treatment in patients with high-risk localized ER+/HER2- cancers.